Human scFv SIgA expressed on Lactococcus lactis as a vector for the treatment of mucosal disease.

The gastrointestinal tract is a complex niche and the main port of entry of many pathogens that trigger a wide range of diseases like inflammatory bowel disease (IBD) and colon cancer. Antibodies are effective for treating such diseases, but a system capable of local delivery at the site of the pathology, thus avoiding systemic side effects, is not yet available. Here we report a novel recombinant scFvSIgA1 protein produced by Lactococcus lactis, anchored to the bacterial membrane, which retains its full immuno-recognizing potential. This scFv fragment employed was specific for a colon cancer epitope, epithelial glycoprotein protein-2 (EGP-2). Accordingly L. lactis expressing this chimeric protein was capable of binding cells expressing this epitope. Expression of specific antibodies on bacteria may allow local delivery of anticancer agents produced by such bacteria in conjunction with the antibody and provides a new avenue in the quest for targeted drug delivery.

[1]  M. Kerr,et al.  A comparison of the binding of secretory component to immunoglobulin A (IgA) in human colostral S‐IgA1 and S‐IgA2 , 2007, Immunology.

[2]  M. Peppelenbosch,et al.  Transgenic probiotica as drug delivery systems: the golden bullet? , 2007, Expert opinion on drug delivery.

[3]  D. Hommes,et al.  Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn’s disease , 2006, Gut.

[4]  A. Herr,et al.  IgA and IgA-specific receptors in human disease: structural and functional insights into pathogenesis and therapeutic potential , 2006, Springer Seminars in Immunopathology.

[5]  D. Hommes,et al.  Immunology of Crohn's Disease , 2006, Annals of the New York Academy of Sciences.

[6]  Erik Remaut,et al.  A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  L. de Leij,et al.  CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia. , 2006, Blood.

[8]  B. Kroesen,et al.  Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells. , 2004, Neoplasia.

[9]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[10]  P. Brandtzaeg,et al.  Transcriptional regulation of the mucosal IgA system. , 2004, Trends in immunology.

[11]  R. Frank,et al.  Ectodomains 3 and 4 of Human Polymeric Immunoglobulin Receptor (hpIgR) Mediate Invasion of Streptococcus pneumoniae into the Epithelium* , 2004, Journal of Biological Chemistry.

[12]  H. Schjerven,et al.  A Novel NF-κB/Rel Site in Intron 1 Cooperates with Proximal Promoter Elements to Mediate TNF-α-Induced Transcription of the Human Polymeric Ig Receptor1 , 2001, The Journal of Immunology.

[13]  S. Withoff,et al.  Bi-specific antibody therapy for the treatment of cancer. , 2001, Current opinion in molecular therapeutics.

[14]  J. Lolkema,et al.  The conserved C-terminus of the citrate (CitP) and malate (MleP) transporters of lactic acid bacteria is involved in substrate recognition. , 2000, Biochemistry.

[15]  M. Glennie,et al.  Clinical trials of antibody therapy. , 2000, Immunology today.

[16]  Martin R. Johnson,et al.  A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  T. Logtenberg,et al.  Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies. , 1999, Cancer research.

[18]  S. Litvinov,et al.  The biology of the 17–1A antigen (Ep-CAM) , 1999, Journal of Molecular Medicine.

[19]  P. Brandtzaeg,et al.  The B‐cell system of human mucosae and exocrine glands , 1999, Immunological reviews.

[20]  E. Vellenga,et al.  Multiple myeloma related cells in patients undergoing autologous peripheral blood stem cell transplantation , 1999, British journal of haematology.

[21]  J. Witte,et al.  Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  B. Kroesen,et al.  Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas , 1998, International journal of cancer.

[23]  J. Lund,et al.  FcαRI (CD89) as a Novel Trigger Molecule for Bispecific Antibody Therapy , 1997 .

[24]  W. D. de Vos,et al.  Controlled gene expression systems for Lactococcus lactis with the food-grade inducer nisin , 1996, Applied and environmental microbiology.

[25]  J. Fagerberg,et al.  Effect of monoclonal antibody 17‐1A and gm‐CSF in patients with advanced colorectal carcinoma—long‐lasting, complete remissions can be induced , 1993, International journal of cancer.

[26]  G. Masucci,et al.  The therapeutic use of the unconjugated monoclonal antibodies (MAb) 17-1a in combination with GM-CSF in the treatment of COLORECTAL CARCINOMA (CRC) , 1993, Medical Oncology and Tumor Pharmacotherapy.

[27]  I. Nes,et al.  High-Frequency Transformation, by Electroporation, of Lactococcus lactis subsp. cremoris Grown with Glycine in Osmotically Stabilized Media , 1989, Applied and environmental microbiology.

[28]  P. Möller,et al.  Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker. , 1987, British Journal of Cancer.

[29]  R. Monteiro,et al.  IgA Fc receptor I signals apoptosis through the FcRgamma ITAM and affects tumor growth. , 2007, Blood.

[30]  Y. Reiter,et al.  Antibodies and their fragments as anti-cancer agents. , 2006, Current pharmaceutical design.

[31]  H. Schjerven,et al.  A novel NF-kappa B/Rel site in intron 1 cooperates with proximal promoter elements to mediate TNF-alpha-induced transcription of the human polymeric Ig receptor. , 2001, Journal of immunology.

[32]  J. Lund,et al.  FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. , 1997, Blood.